Study of a pill to raise low platelets after chemo
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This study tests an investigational pill (hetrombopag) to see if it can safely raise platelet counts in people with solid tumors whose platelets drop after chemotherapy. If you are receiving platinum- or gemcitabine-based chemo and have low platelets due to chemo, this trial may be an option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have a solid tumor cancer (like lung, breast, ovarian, bladder, pancreatic, or colon cancer).
- You must be receiving chemotherapy that includes a platinum drug or gemcitabine, given in 21-day cycles.
- You should be able to care for yourself (ECOG score 0–2) and have a life expectancy of 6 months or more.
- Your low platelet count must be caused by chemotherapy — not by other conditions like liver disease, an enlarged spleen, or a bleeding disorder.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if hetrombopag can prevent low platelet counts caused by chemotherapy in people with gastrointestinal cancers. It may help reduce the risk of bleeding and the need for platelet transfusions.
This trial tests a drug called hetrombopag to help raise platelet counts in women whose cancer therapy has caused low platelets. The goal is to see if it can safely prevent the need for platelet transfusions.
This study tests if a combination of two medications, hetrombopag (a pill) and rhTPO (an injection), can safely raise very low platelet counts in people with solid tumors caused by their cancer treatments. If you have low platelets due to chemo, radiation, or other therapies, this may offer a new option.
This Phase 2 study tests eltrombopag to help people with low platelet counts caused by chemotherapy (which can increase bleeding risk). It looks at whether raising platelets can reduce bleeding problems and help you stay on track with care.
This Phase 2 study tests hetrombopag to treat chemotherapy-related low platelet counts in adults with acute myeloid leukemia (AML) in remission. It aims to help keep platelets up so you can safely continue chemotherapy.
This trial tests a drug called Hetrombopag to see if it can prevent low platelet counts in people with advanced lung cancer who are receiving certain types of chemotherapy. The goal is to help keep platelet levels safe so you can continue your cancer treatment without delays or dose reductions.
Hear when a new Patients With Chemotherapy-Induced Thrombocytopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.